Statement Of Cash Flows [Abstract]

Marinomed Biotech AG - Filing #997033

Concept As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
As at
2020-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
- EUR
- EUR
6,398 EUR
6,398 EUR
- EUR
- EUR
5,891 EUR
5,891 EUR
Adjustments to reconcile profit (loss) [abstract]
Adjustments for finance costs
2,672 EUR
1,550 EUR
Adjustments for decrease (increase) in inventories
5,347,000 EUR
1,013,000 EUR
Adjustments for depreciation and amortisation expense
6,697,000 EUR
6,089,000 EUR
Adjustments for provisions
- EUR
7,630,000 EUR
Income taxes paid (refund), classified as operating activities
68,000 EUR
1,971,000 EUR
Cash flows from (used in) operating activities
5,203 EUR
4,866 EUR
Cash flows from (used in) investing activities [abstract]
Proceeds from sales of property, plant and equipment, classified as investing activities
201,000 EUR
- EUR
Cash flows from (used in) investing activities
2,075,000 EUR
9,188,000 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from borrowings, classified as financing activities
6,200 EUR
1,800 EUR
Payments of lease liabilities, classified as financing activities
164,000 EUR
231,000 EUR
Cash flows from (used in) financing activities
7,784 EUR
2,380 EUR
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
14,000 EUR
346,000 EUR
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes
2,373 EUR
3,405 EUR
Cash and cash equivalents
8,175 EUR
5,802 EUR
9,207 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.